As reported on PharmaBiz, the US Food and Drug Administration (FDA) has approved Novo Nordisk’s higher‑dose formulation of semaglutide, Wegovy HD (7.2 mg once weekly), for chronic weight management. The decision allows the therapy to be used both to reduce excess body weight and to help patients maintain weight loss over time. As part of the review, the FDA granted a Commissioner’s National Priority Voucher, a designation that shortens regulatory timelines for products addressing urgent public health needs.
The approval is supported by findings from Novo Nordisk’s STEP UP phase 3 clinical program. In the pivotal STEP UP trial, adults with obesity receiving once‑weekly semaglutide 7.2 mg achieved an average weight reduction of just over 20% after 72 weeks when combined with lifestyle intervention. Approximately one‑third of participants lost at least 25% of their baseline body weight. A parallel STEP UP T2D study showed that participants with obesity and type 2 diabetes experienced a mean weight loss of more than 14% with the higher dose.
Across trials, the safety and tolerability profile of semaglutide 7.2 mg was consistent with previous experience with GLP‑1 receptor agonist–based weight management therapies. Adverse events were generally in line with established semaglutide use, reinforcing confidence in the higher‑dose regimen.
Novo Nordisk positions Wegovy HD as an expansion of its obesity treatment portfolio. Wegovy has been available in the US since 2021, and the company has since introduced both oral and injectable options at different doses. According to the company, Wegovy HD offers an additional alternative for patients who may benefit from greater weight loss outcomes under medical supervision.
The company plans to launch Wegovy HD in the US in April 2026, delivered via a single‑dose pen. The 7.2 mg dose is already approved for adults with obesity in the European Union and the UK, with further regulatory decisions on the single‑dose pen presentation expected in those regions in the second half of 2026.
Beyond weight management, Wegovy has regulatory approvals covering several related indications, including reduction of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity. Injectable Wegovy is also approved for adolescents aged 12 years and older with obesity and, in adults, for the treatment of metabolic dysfunction–associated steatohepatitis (MASH) with moderate to advanced fibrosis, excluding cirrhosis.
Novo Nordisk, founded in 1923 and headquartered in Denmark, continues to focus its research and commercial strategy on chronic diseases such as obesity, diabetes, and cardiovascular conditions, aiming to broaden access to treatments that address long‑term health risks.
